$XTALPI(02228.HK)'s earnings report tomorrow is highly anticipated, but "far exceeding expectations" requires historical revenue, profit, and cash flow to be significantly higher than analysts' forecasts, along with a substantial upward revision of future guidance and a clear timeline for large orders and commercialization, to potentially reverse the trend.

However, the real-world challenges are prominent: the price-to-sales ratio still exceeds 50 times, far above the industry average, and expectations are already largely priced in; while news flow is lively, cash flow conversion will take 2-3 years, lacking sustained large orders to support the current market cap. Compared to Schrödinger and Recursion Pharmaceuticals, with market caps of only HKD 6.8 billion and HKD 13.2 billion respectively, their valuations are more restrained.

For this reason, cutting losses is more important than making profits. A 25% floating loss requires about a 35% gain to break even; the larger the loss, the harder it is to recover. Don't pin all your hopes on a single earnings report. Focus on hard metrics like cash flow, strictly control your position size, and maintain rationality—this is the way to survive in the long run.